BioVie (BIVI) Q4 2026 earnings summary

Executive summary

• Clinical-stage company focused on drug therapies for neurological, neurodegenerative disorders, and advanced liver disease.

• Lead programs include bezisterim (NE3107) for Alzheimer's, Parkinson's, and long COVID, and BIV201 (terlipressin) for liver cirrhosis complications.

• No commercial products or revenues to date; operations funded by equity offerings and grants.

Financial highlights

• Net loss for the year ended June 30, 2026 was $22.1 million, up from $17.5 million in 2025, driven by increased R&D expenses.

• Operating expenses rose to $22.7 million from $18.1 million year-over-year, mainly due to higher clinical study costs.

• R&D expenses increased by $4.7 million to $14.0 million, reflecting expanded clinical trial activity.

• Cash and cash equivalents at June 30, 2026 were $9.0 million, with working capital of $9.8 million and accumulated deficit of $374.3 million.

• No revenues recognized; grant reimbursements for long COVID trial totaled $7.6 million in 2026.

Outlook and guidance

• Future operations depend on successful clinical development and additional capital raises.

• Management expects to seek further funding through equity sales, loans, or strategic transactions.

• Substantial doubt exists about the company's ability to continue as a going concern without new financing.